title: The HIV-specific advance directive.
abstract: OBJECTIVE
  To determine whether persons living with HIV find a disease-specific advance directive more acceptable than a generic directive.
  
  
  METHODS
  Randomized clinical trial.
  
  
  METHODS
  HIV consumer organization and hospital-based HIV clinic.
  
  
  METHODS
  Volunteer sample of persons with HIV.
  
  
  METHODS
  The disease-specific HIV Living Will, the generic Centre for Bioethics Living Will, or both.
  
  
  RESULTS
  Of 101 participants who received both advance directives, 78 (77.2%) preferred the disease-specific HIV Living Will and 23 (22.8%) preferred the generic Centre for Bioethics Living Will (p < .001). Most participants who preferred the HIV Living Will did so because it was more specific or relevant to their situation.
  
  
  CONCLUSIONS
  Persons living with HIV prefer a disease-specific to a generic advance directive. They should be offered a disease-specific advance directive. Our findings should also encourage investigators to develop and evaluate disease-specific advance directives in other clinical settings.
authors.affiliation: University of Toronto Joint Centre for Bioethics, Department of Medicine, University of Toronto, Canada.
authors.forename: P A
authors.initials: PA
authors.lastname: Singer
authors.forename: E C
authors.initials: EC
authors.lastname: Thiel
authors.forename: I
authors.initials: I
authors.lastname: Salit
authors.forename: W
authors.initials: W
authors.lastname: Flanagan
authors.forename: C D
authors.initials: CD
authors.lastname: Naylor
mesh_terms: D000328:Adult; D001290:Attitude; D005260:Female; D015658:HIV Infections; D006801:Humans; D016224:Living Wills; D008297:Male